Generic API researchSynthetic API

Omgene Life Science has expertise in development of Complex steroids, anti-tubercular drugs, deuteriated APIs, Sugar & cyclodextrin derivatives, Anti-viral and anti-diabetic Actives.

  1. Brexanolone is a  naturally occurring   neurosteroid which is made in the body from the  hormone  progesterone. As a medication, brexanolone is also referred to as allopregnanolone.
  2. Nitisinone, is a  medication  used to slow the effects of  hereditary tyrosinemia type 1 (HT-1)
  3. Sugammadex, sold under the brand name Bridion, is a medication for the reversal of  neuromuscular blockade  induced by  rocuronium  and  vecuronium in  general anaesthesia. It is the first  selective relaxant binding agent (SRBA). 
  4. Saroglitazar is a drug for the treatment of  type 2 diabetes mellitus  and  dyslipidemia. It is approved for use in India by the  Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and  hypertriglyceridemia  with type 2 diabetes mellitus not controlled by  statin therapy. 
  5. Brivaracetam, is a chemical analog of  levetiracetam , is a  racetam derivative with  anticonvulsant (antiepileptic) properties.
  6. Bedaquiline: a quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria. It has a role as an antitubercular agent and an ATP synthase inhibitor. It is a member of quinolines, a member of naphthalenes, an organobromine compound, an aromatic ether, a tertiary alcohol and a tertiary amino compound. It is a conjugate base of a bedaquiline(2+).
  7. Mebendazole: a carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5. It has a role as an antinematodal drug, a tubulin modulator and a microtubule-destabilising agent. It is a member of benzimidazoles, a carbamate ester and an aromatic ketone. It derives from a hydride of a 1H-benzimidazole.
  8. Isavuconazonium sulfate: an azaheterocycle sulfate salt that is a prodrug for isavuconazole, an antifungal agent used for the treatment of invasive aspergillosis and invasive mucormycosis. It has a role as a prodrug, an ergosterol biosynthesis inhibitor, an EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor and an orphan drug. It is an azaheterocycle sulfate salt, a triazole antifungal drug and a conazole antifungal drug. It contains an isavuconazonium.
  9. Rufinamide: a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
  10. Selexipag: a member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). It has a role as an orphan drug, a prostacyclin receptor agonist, a platelet aggregation inhibitor, a vasodilator agent and a prodrug. It is a monocarboxylic acid amide, an ether, a member of pyrazines, an aromatic amine, a tertiary amino compound and a N-sulfonylcarboxamide. It is functionally related to an ACT-333679.
  11. Apremilast: a member of the class of isoindoles that is isoindole-1,3-dione substituted at position 4 by an acetamido group and at position 1 by a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl group. Used for treatment of psoriatic arthritis. It has a role as a phosphodiesterase IV inhibitor and a non-steroidal anti-inflammatory drug. It is an aromatic ether, a N-acetylarylamine, a sulfone and a member of phthalimides.
  12. Molnupiravir: a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It is functionally related to a N(4)-hydroxycytidine.

Brexanolone

Apremilast

Bedaquiline

Brivaracetam

Deutetrabenazine

Isavuconazonium Sulfate

Molnupiravir

Nitisinone

Rufinamide

Saroglitazar

Selexipag

Sugammadex